Case Report: Recurrent supraglottitis in a patient with metastatic melanoma treated with ipilimumab and nivolumab
Palmeri M, Weiss S, Purnell P. Case Report: Recurrent supraglottitis in a patient with metastatic melanoma treated with ipilimumab and nivolumab. Frontiers In Oncology 2025, 15: 1615835. PMID: 40936685, PMCID: PMC12420325, DOI: 10.3389/fonc.2025.1615835.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune checkpoint inhibitorsMetastatic melanoma treated with ipilimumabRare immune-related adverse eventImmune checkpoint inhibitors rechallengeMelanoma treated with ipilimumabMetastatic mucosal melanomaResponse to steroidsStandard of careNivolumab monotherapyCheckpoint inhibitorsAdvanced melanomaMucosal melanomaAirway compromiseSupraglottic edemaAdverse eventsAirway obstructionGlobus sensationClinical challengeAirway diseaseEarly recognitionLaryngoscopic evaluationSupraglottitisNivolumabMelanomaLifileucel tumor‐infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors
Kluger H, Grigoleit G, Thomas S, Domingo‐Musibay E, Chesney J, Sanmamed M, Medina T, Ziemer M, Whitman E, Finckenstein F, Gastman B, Chou J, Wu X, Sulur G, Fiaz R, Qi R, Sarnaik A. Lifileucel tumor‐infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors. Cancer Communications 2025 PMID: 40693376, DOI: 10.1002/cac2.70050.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply